Mauro Ferrari

Mauro Ferrari, Ph.D. – Biosketch (Updated June 2, 2019) Current Positions (Selected): President Designate, European Research Council of the European Union (primary funding agency for research in the 28 member Countries of EU); Director, Arrowhead Pharmaceuticals (NASDAQ:ARWR); Executive Vice President for Strategic Initiatives and Community Partnerships, and Professor, University of St. Thomas; Advisor, Houston Methodist Hospital and Research Institute. Education: Mathematics (Padova, Italy, 1985, Dottore); Mechanical Engineering (University of California Berkeley, 1987, MS and 1989, PhD); Medicine (Ohio State University, 2002-2003, no degree); Business Administration (Wharton, 2016, Harvard Business School, 2017, no degree). Professional History (Selected): 1988-1990 Universita’ di Udine, Italy (Ricercatore, Assistant Professor Civil Engineering); 1991-1998 University of California Berkeley (Assistant and Associate Professor with tenure, Civil and Environmental Engineering, Materials Science and Engineering, Bioengineering); 1998-2006 The Ohio State University (Full Professor with tenure and endowed chair, Biomedical Engineering, Mechanical Engineering, Internal Medicine, Director of Biomedical Engineering, Associate Director Davis Heart and Lung Research Institute, Associate Vice President Health Science Technology Commercialization); 2003-2005 National Cancer Institute (Special Expert on Nanomedicine and Advisor to Director, concurrent with OSU); 2006-2010 University of Texas Medical School Houston, and MD Anderson Cancer Center (Full Professor with tenure and endowed chair, Internal Medicine, Experimental Therapeutics, Biomedical Engineering and Nanomedicine); 2010-2019 Houston Methodist Hospital (HMH) and Research Institute (HMRI) (Full professor with presidential endowed chair, President and CEO of HMRI, Executive Vice President of HMH, Chief Commercialization Officer).